NovoRapid®
: no other
rapid-acting insulin is part of so many lives2
The most prescribed rapid- acting insulin worldwide,2 backed by over a decade of clinical use1
Approved for every stage of life, starting from children aged 2 years to the elderly1
Helps patients attain and maintain their HbA1c
goals3
Pre- and post-meal dosing allows patients to treat according to lifestyle4
FlexPen® : used by millions worldwide5,6
NovoRapid® NovoRapid®
Insulin aspart 10ml. NovoRapid® Penfi ll® 3ml. NovoRapid® FlexPen® 3ml.
All presentations contain insulin aspart 100 units/ml. Presentation: A disposable, dial-a-dose delivery device able to deliver 1–60 units in increments of 1 unit, containing a solution of insulin aspart. Available in a strength of 100 U/ml; each device contains 3ml. NovoRapid®
FlexPen®
is colour coded. Indication: Treatment of diabetes mellitus in adults and adolescents and children aged 2 to 17 years. Dosage and administration: Individual by subcutaneous injection. It should normally be used in combination with intermediate or long-acting insulin given at least once a day. NovoRapid®
of action than soluble human insulin and should generally be given immediately before a meal. When necessary NovoRapid®
has a faster onset and a shorter duration can be given
or basal dose. May also be used in a suitable pump system for continuous subcutaneous insulin infusion. If necessary may be administered intravenously by healthcare professional. Contraindications: Hypersensitivity to active substance or excipients. Special warnings and special precautions: Inadequate dosing or discontinuation of treatment may lead to hyperglycaemia and diabetic ketoacidosis, which is potentially lethal. Travelling between time zones may require change in the applied insulin regimen. Omission of a meal, unplanned strenuous physical exercise or too high a dose in relation to insulin requirements may lead to hypoglycaemia. Patients whose blood glucose control is greatly improved may experience a change in their usual warning symptoms of hypoglycaemia. Usual warning symptoms may disappear in patients with longstanding diabetes. If hypoglycaemia occurs, it may occur earlier after an injection compared with soluble human insulin. Changes in early warning symptoms of hypoglycaemia may occur on transfer between different types of insulin products. The fast onset of action should be considered in patients where a delayed absorption of food might be expected. Transferring to another type or brand of insulin should be done under strict medical supervision. Patients transferred to NovoRapid®
soon after a meal. Blood glucose monitoring and dose adjustments are recommended to achieve optimal glycaemic control. In elderly patients, patients with renal or hepatic impairment, glucose monitoring should be intensifi ed and insulin aspart dosage adjusted on an individual basis. No studies in children under the age of 2 years; should only be used in this age group under careful medical supervision. Can be used in children in preference to soluble insulin when a fast onset of action might be benefi cial. Transfer from other insulin products, may require adjustment of the NovoRapid®
from another type of insulin may require an
increased number of daily injections or a change in dosage. Injection site reactions, usually transitory, may occur; rotation of injection sites within an area may help reduce or prevent these reactions. Rarely injection site reactions may require discontinuation of NovoRapid®
. Hypoglycaemia
may constitute a risk when driving or operating machinery. NovoRapid® must not be mixed with other medicinal products except for NPH (Neutral Protamine Hagedorn) insulin and some infusion fl uids. Consult
Summary of Product Characteristics for details. Pregnancy and lactation: NovoRapid®
can be used in pregnancy. No restrictions on use
during breast-feeding. Undesirable effects: Very common (1/10); common (1/100 to PL number: NovoRapid® NovoRapid®
Penfi ll® , 5 x 3ml EU/1/99/119/003. NovoRapid®
, 1 x 10ml EU/1/99/119/001. FlexPen®
£28.84. 5 x 3ml FlexPen® ,
5 x 3 ml EU/1/99/119/009. Legal category: POM. Basic NHS price: 1 x 10ml vial £16.28. 5 x 3ml Penfi ll®
Full prescribing information can be obtained from: Novo Nordisk Limited, Broadfi eld Park, Brighton Road, Crawley, West Sussex, RH11 9RT. Date last revised: Nov 2009.
Adverse events should be reported. Reporting forms and information can be found at
www.yellowcard.gov.uk. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be monitored for training purposes.
Changing Diabetes® , FlexPen® , NovoRapid® trademarks of Novo Nordisk A/S.
APROM ID#2262; approval date: July 2010 UK/NR/0810/0024 References: 1. NovoRapid®
Summary of Product Characteristics.
2. IMS Health Inc. IMS MIDAS (MATQ209). 3. Holman RR et al. for the 4-T Study Group. Three-year effi cacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009; 361(18): 1736–1747. 4. Brunner GA et al. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med. 2000; 17(5): 371–375. 5. IMS Health Inc. IMS MIDAS (MATQ210). 6. Reimer T. Intuitiveness, instruction time, and patient acceptance of a prefi lled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes. Clin Ther. 2008; 30(12): 2252–2262.
, and Penfi ll® are registered £32.00.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68